News | January 07, 2015

RSNA Research Demonstrates Benefit of Volpara Volumetric Breast Analytics for Dense Breast Assessment

Six abstracts cover topics including patient-specific dose, applied pressure

January 7, 2015 — The value of volumetric breast imaging data to provide critical insight for optimal breast imaging quality and workflow was the focus of numerous abstracts accepted for presentation at the 100th Annual Meeting of the Radiology Society of North America (RSNA), November 30-December 5, 2014. 

According to Volpara Solutions, six abstracts highlight the use of quantitative breast imaging software tools to provide breast imaging and analytics data. Presented data types including volumetric density, patient-specific dose, applied pressure and other factors designed to maintain accuracy and consistent quality in breast screening using digital mammography and digital breast tomosynthesis.

In the scientific exhibit, “Can we use the manufacturer reported mammography dose to inform patients?” (BRS263), researchers from Elizabeth Wende Breast Center reviewed manufacturer-reported mean-glandular dose (MGD) for 30 women who had undergone sequential screening mammograms on a mix of three manufacturers’ systems. The manufacturer-reported MGD varied considerably sequential mammograms and between manufacturers, with changes ranging from -2.87 to +4.31 mGy.  Additionally, since the algorithms used by manufacturers vary, the estimations are not easily compared.

This is consistent with other research, which has demonstrated that mammography units routinely under- or overestimate dose because they do not include the patient’s specific volumetric breast density in the estimation. In another abstract examining patient dose in mammography, “System-wide monitoring of mammographic radiation dose for quality assurance”, researchers from Weinstein Imaging used VolparaAnalytics on more than 11,000 images to compare manufacturer-reported MGD to a patient-specific estimate. Automated stratification of the data by mammography unit suggested that one vendor underestimated MGD compared to the patient-specific dose calculations, despite similar breast density characteristics of the populations. The abstract concludes that for more accurate reporting of MGD, it is essential that a standardized method be used across all manufacturers’ systems.

"At Weinstein Imaging, we want to ensure our patients are safe and informed during screening. Part of that includes monitoring and recording patient dose. Volpara enables true comparison of dose across machines so that we can spot issues early and truly keep women safe and informed," said Marcela Böhm-Vélez, practicing radiologist and president of Weinstein Imaging.

Accurate breast density estimation is important for breast cancer risk assessment and guiding personalized breast screening recommendations. In the presentation, “Fully automated volumetric breast density estimation from digital breast tomosynthesis images: Multimodality comparison with digital mammography and breast MRI”, researchers from the University of Pennsylvania reviewed results of a study to evaluate the feasibility of automated volumetric breast density for breast tomosynthesis and compared the results to digital mammography and breast magnetic resonance imaging (MRI). The abstract concludes that volumetric breast density estimates from breast tomosynthesis data sets were highly correlated to density estimates from digital mammography and MRI, and hold the potential for more accurate density assessments and more accurate measures of breast cancer risk. 

In addition, the “Breast Imaging Breast Density & Risk Assessment” session included three presentations that featured VolparaDensity: ”Automated volumetric breast density and risk of cancer stratified by pathological attributes,” “Comparing breast density measurement techniques in screening digital mammography” and  “The diagnostic effect of digital breast tomosynthesis in relation to visually assessed and automated volumetric breast density.”  The role of volumetric density in adjunctive imaging for women with dense breasts was the topics of numerous presentations.

For more information: www.volparasolutions.com

Related Content

Imago Systems Announces Collaboration With Mayo Clinic for Breast Imaging

Image courtesy of Imago Systems

News | Mammography | August 14, 2019
Image visualization company Imago Systems announced it has signed a know-how license with Mayo Clinic. The multi-year...
Artificial Intelligence Could Yield More Accurate Breast Cancer Diagnoses
News | Artificial Intelligence | August 13, 2019
University of California Los Angeles (UCLA) researchers have developed an artificial intelligence (AI) system that...
Lake Medical Imaging Selects Infinitt for Multi-site RIS/PACS
News | PACS | August 09, 2019
Infinitt North America will be implementing Infinitt RIS (radiology information system)/PACS (picture archiving and...
Volpara to Distribute Screenpoint Medical's Transpara AI Solution
News | Breast Imaging | August 02, 2019
Volpara Solutions and ScreenPoint Medical BV signed an agreement under which Volpara will sell ScreenPoint's Transpara...
Ikonopedia Releases Automated Combined Reporting Package at AHRA
News | Mammography Reporting Software | July 26, 2019
Ikonopedia showcased its recently released Automated Combined Reporting package and its entire suite of structured...
Hologic Partners With MagView to Develop Unifi EQUIP Solution
Technology | Mammography Reporting Software | July 25, 2019
Hologic announced a partnership with mammography information solutions provider MagView to develop Unifi EQUIP, an...
Fujifilm Releases Tomosynthesis Biopsy Option for Aspire Cristalle Mammography System
Technology | Breast Biopsy Systems | July 24, 2019
Fujifilm Medical Systems U.S.A. Inc. recently expanded its breast imaging solutions with the launch of its...
IBM collected a dataset of 52,936 images from 13,234 women who underwent at least one mammogram between 2013 and 2017.

IBM collected a dataset of 52,936 images from 13,234 women who underwent at least one mammogram between 2013 and 2017, and who had health records for at least one year prior to the mammogram. The algorithm was trained on 9,611 mammograms. Image courtesy of Radiology.

Feature | Artificial Intelligence | July 19, 2019 | Michal Chorev
Breast cancer is the global leading cause of cancer-related deaths in women, and the most commonly diagnosed cancer...
Paragon Biosciences Launches Qlarity Imaging to Advance FDA-cleared AI Breast Cancer Diagnosis System

Qlarity Imaging’s software is used to assist radiologists in the assessment and characterization of breast lesions. Imaging features are synthesized by an artificial intelligence algorithm into a single value, the QI score, which is analyzed relative to a database of reference abnormalities with known ground truth. Image courtesy of Business Wire.

Technology | Artificial Intelligence | July 18, 2019
Paragon Biosciences LLC announced the launch of its seventh portfolio company, Qlarity Imaging LLC, which was founded...
FDA Clears Koios DS Breast 2.0 AI-based Software
News | Ultrasound Women's Health | July 11, 2019
Koios Medical announced its second 510(k) clearance from the U.S. Food and Drug Administration (FDA).